Tejas Patil - Concepedia

Author

Tejas Patil

Also Known As

Patil, T, Patil, T., Patil, Tejas, Patil,T., Schwartzman, William, T Patil, T. Patil, Tanushri Patil, Tejas Patil, Tejas S. Patil

184

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

University of Colorado Denver Memorial Sloan Kettering Cancer Center University of Colorado Anschutz Medical Campus University of Colorado Cancer Center The University of Texas MD Anderson Cancer Center

About

Tejas Patil is an author at University of Colorado Denver specializing in oncology, medicine, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	22	1.8K
2	Health Sciences	4	4	522
3	Engineering	2	2	112
4	Cell Biology	2	2	33
5	Endocrinology	1	1	15

Tejas Patil

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Non–Small Cell Lung Cancer, Version 4.2024 Gregory J. Riely, Douglas E. Wood, David S. Ettinger, Journal of the National Comprehensive Cancer Network Tumor BiologyActionable Molecular BiomarkersAdvanced Lung DiseaseVersion 4.2024Medicine	2024	614
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023 David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Journal of the National Comprehensive Cancer Network	2023	449
Management of Brain Metastases in Tyrosine Kinase Inhibitor–Naïve Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis William J. Magnuson, N.H. Lester-Coll, Abraham J. Wu, Journal of Clinical Oncology Neuro-oncologyBrain MetastasesRadiation TherapyMedicineCancer Management	2017	448
The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non–Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib Tejas Patil, Derek Smith, Paul A. Bunn, Journal of Thoracic Oncology Neuro-oncologyTumor InnervationBrain MetastasesMalignant DiseaseMedicine	2018	193
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC Alexander Drilon, Chao‐Hua Chiu, Yun Fan, JTO Clinical and Research Reports	2022	111
Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation Nicholas J. Thomas, Nathaniel J. Myall, Fangdi Sun, Journal of Thoracic Oncology	2021	105
A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics Danh-Tai Hoang, Gal Dinstag, Eldad D. Shulman, Nature Cancer Deep-learning FrameworkSystems BiologyEngineeringMachine LearningCancer Treatment Response	2024	100
Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer Terry L. Ng, Yiwei Liu, Anastasios Dimou, Cancer	2018	79
ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events Terry L. Ng, Derek Smith, Rao Mushtaq, Journal of Thoracic Oncology Autoimmune DiseaseDisease MechanismGenetic DisorderGeneticsPathogenesis	2018	73
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers Xiuning Le, Christina S. Baik, Jessica R. Bauman, The Oncologist	2022	46

Page 1